Oncology and inflammation
Our inflammation and oncology franchises are focused on helping to improve the lives of patients with life-threatening or chronic diseases.
Offering new biosimilars for the treatment of these diseases is one way we’re committed to improving patients’ lives. Because of their lower costs, biosimilars have the potential to reach more patients and support a sustainable drug care system. And that’s a good thing because biologic treatments for oncology and inflammation have changed the outlook for people with these diseases and everyone who cares for them.
Biologics in oncology
At Amgen, we are experienced in the science of creating and manufacturing biologics.
Our oncology portfolio includes:1,2
recently approved biosimilar medicine, and several others in development
innovative medicines in different phases of clinical development
Our history with oncology biologics includes not only the discovery, development, and production of these practice-changing medicines, but also our innovative delivery systems to help increase access and adoption.
Biologics for chronic inflammatory diseases
Biologics for chronic inflammatory diseases, such as rheumatoid arthritis, were a true advance. With their advent, the treatment plan was no longer about managing symptoms, but about helping to put the disease into remission by inhibiting specifically targeted biochemical pathways of inflammation.3
Amgen has a global pipeline that is rich in biosimilars that treat inflammation.3
References: 1. Health Canada Drug Product Database. 2. Amgen Pipeline. www.amgenpipeline.com/pipeline. Accessed August 21, 2018. 3. Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77-87.